PDCD1 and non-small cell lung carcinoma: It occurs in up to 5% of patients receiving anti-PD1 and anti-PDL1, while it arises in 10% of patients receiving combination treatment [38, 60, 61], with higher odds of pneumonitis in non-small cell lung cancer compared with melanoma [61–63].